Wedmont Private Capital’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$893K Sell
5,202
-636
-11% -$120K 0.02% 379
2026
Q1
$1.19M Sell
5,838
-113
-2% -$21.8K 0.04% 271
2025
Q4
$1.13M Buy
5,951
+523
+10% +$91.7K 0.04% 261
2025
Q3
$932K Sell
5,428
-56
-1% -$8.48K 0.03% 290
2025
Q2
$777K Buy
5,484
+48
+0.9% +$6.73K 0.03% 327
2025
Q1
$721K Buy
5,436
+158
+3% +$22.9K 0.04% 287
2024
Q4
$707K Buy
5,278
+19
+0.4% +$2.66K 0.04% 292
2024
Q3
$808K Buy
5,259
+446
+9% +$72K 0.05% 247
2024
Q2
$763K Buy
4,813
+337
+8% +$50.7K 0.05% 249
2024
Q1
$612K Buy
4,476
+541
+14% +$71.6K 0.04% 280
2023
Q4
$545K Buy
3,935
+594
+18% +$77.2K 0.04% 285
2023
Q3
$448K Buy
3,341
+675
+25% +$92.2K 0.05% 279
2023
Q2
$359K Buy
2,666
+80
+3% +$11.8K 0.04% 335
2023
Q1
$373K Buy
2,586
+106
+4% +$14.3K 0.05% 279
2022
Q4
$351K Buy
2,480
+269
+12% +$33.7K 0.05% 299
2022
Q3
$243K Buy
2,211
+87
+4% +$11K 0.05% 311
2022
Q2
$281K Buy
2,124
+530
+33% +$69.5K 0.06% 252
2022
Q1
$212K Buy
+1,594
New +$191K 0.05% 304

Other funds holding AZN

Wedmont Private Capital's AZN Position: Q2 2026 in Review

Wedmont Private Capital reduced its AstraZeneca (AZN) stake by 11% in Q2 2026, selling an estimated $120K and leaving 5,202 shares worth $893K. The position accounts for 0.02% of the portfolio, ranked #379.

Wedmont Private Capital first reported a position in AZN in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.19M in Q1 2026. 443 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Wedmont Private Capital held 5,202 shares of AstraZeneca worth $893K as of Q2 2026.
  • Wedmont Private Capital sold 636 AstraZeneca shares in Q2 2026, an estimated $120K.
  • AstraZeneca made up 0.02% of Wedmont Private Capital's portfolio in Q2 2026, its #379 holding.
  • Wedmont Private Capital first reported a position in AstraZeneca in Q1 2022 and has held it in 18 quarters since.
  • Wedmont Private Capital's AstraZeneca position peaked at $1.19M in Q1 2026.
  • 443 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Wedmont Private Capital's 13F filing for Q2 2026, filed 13 Jul 2026.